Midkine (MDK) in cancer and drug resistance: from inflammation to therapy
Abstract Midkine (MDK) is a heparin-binding growth factor implicated in the pathogenesis of various diseases, including cancer, chronic inflammation, and multidrug resistance (MDR). While its expression is minimal in adult tissues, it becomes markedly elevated during embryogenesis and in response to...
Saved in:
| Main Authors: | Berna Yıldırım, Kudret Kulak, Ayhan Bilir |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02941-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Coordinated changes in midkine expression and midkine-associated multiomic profile in glioma microenvironment
by: Mieszko Lachota, et al.
Published: (2025-08-01) -
Targeting the MDK/c‐Myc complex to overcome temozolomide resistance in glioma
by: Xiaonan Xi, et al.
Published: (2025-06-01) -
Midkine Serum Levels in Inflammatory and Non-Inflammatory Dilated Cardiomyopathy
by: Ulrich Grabmaier, et al.
Published: (2025-02-01) -
Is there an association between mIDkIne levels and the prognosis of COVID-19 disease?
by: D. Çekiç, et al.
Published: (2023-05-01) -
Relationship between serum Midkine and Omentin-1 levels and the severity of sepsis in patients and their prognostic value
by: Lin Gao, et al.
Published: (2024-12-01)